Comparison of neoadjuvant chemoimmunotherapy and neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma: a retrospective study with 3-year survival analysis
nCIT demonstrated superior pathological response rates and improved 3-year DFS and OS compared to nCT alone in locally advanced ESCC, but long-term survival validation is needed.
Authors
- Derong Zhang (ORCID: https://orcid.org/0000-0002-2479-0591)
- Feng Wang (ORCID: https://orcid.org/0000-0003-4548-2309)
- Pengqiang Gao (ORCID: https://orcid.org/0000-0001-9692-8433)
- Mengxia Lei
- Hui‐Hui Lin (ORCID: https://orcid.org/0000-0002-3514-0391)
- Yujie Chen (ORCID: https://orcid.org/0000-0002-6285-4074)
- Peng Chen (ORCID: https://orcid.org/0000-0002-5810-8159)
- Weijie Chen (ORCID: https://orcid.org/0000-0002-9780-1167)
- Hao He (ORCID: https://orcid.org/0000-0001-7029-6992)
- Shuoyan Liu (ORCID: https://orcid.org/0000-0003-3749-1256)
- Peiyuan Wang
- Feng-Nian Zhuang
- Jun-Peng Lin
- Wenwei Wei
- Hang Zhou (ORCID: https://orcid.org/0000-0003-0158-2244)
Institutions
- Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1007/s00432-024-06004-w
- Citations
- 10
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.73
Funders
- National Natural Science Foundation of China
- Fujian Medical University